|The R788 n/a (Catalog #MBS8506248) is a Kinase Inhibitor and is intended for research purposes only. The product is available for immediate purchase.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given kinase inhibitor. We\'ve tested the R788 (Fostamatinib disodium) with the following immunoassay(s):
R935788 (Fostamatinib disodium) is a selective Syk inhibitor with an IC50 of 41 nM.R935788 (Fostamatinib disodium) has shown clinical activity in heavily pre-treated NHL and CLL patients, exhibits inhibitory activity against SYK but also inhibits a broad spectrum of other kinase targets. In addition to blocking Fc gamma R-mediated events, R935788 (Fostamatinib disodium) also blocked BCR-mediated Ag presentation, thus broadly interrupting the humoral contributions to T cell-driven autoimmunity. Indeed, oral administration of R935788 (Fostamatinib disodium) significantly delayed spontaneous diabetes onset in NOD mice and successfully delayed progression of early-established diabetes even when treatment was initiated after the development of glucose intolerance. At the DC level, R788 treatment was associated with reduced insulin-specific CD8 priming and decreased DC numbers. At the B cell level, R935788 (Fostamatinib disodium) reduced total B cell numbers and total Ig concentrations. Interestingly, R935788 (Fostamatinib disodium) increased the number of IL-10-producing B cells, thus inducing a tolerogenic B cell population with immunomodulatory activity. Taken together, Syk in APCs is an attractive target in T cell-mediated autoimmune diseases such as type 1 diabetes. .
Solubility: Unknown. Formula: C23H24FN6O9P.2Na
CAS Number: 1025687-58-4.